KRIT1: A traffic warden at the busy crossroads between redox signaling and the pathogenesis of Cerebral Cavernous Malformation disease

A Perrelli, C Ferraris, E Berni, AJ Glading… - Antioxidants & Redox …, 2023 - liebertpub.com
Significance: KRIT1 (Krev interaction trapped 1) is a scaffolding protein that plays a critical
role in vascular morphogenesis and homeostasis. Its loss-of-function has been …

Molecular biomarkers and drug targets in brain arteriovenous and cavernous malformations: where are we?

V Venugopal, S Sumi - Stroke, 2022 - Am Heart Assoc
Vascular malformations of the brain (VMB) comprise abnormal development of blood
vessels. A small fraction of VMBs causes hemorrhages with neurological morbidity and risk …

Non–beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma

CT Seebauer, MS Graus, L Huang… - The Journal of …, 2022 - Am Soc Clin Investig
Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are
composed of R (+) and S (–) enantiomers: the R (+) enantiomer is largely devoid of beta …

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

W Li, R Shenkar, MR Detter, T Moore… - The Journal of …, 2021 - Am Soc Clin Investig
Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce
cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been …

Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot …

S Lanfranconi, E Scola, JMTA Meessen… - The Lancet …, 2023 - thelancet.com
Background Observations in people with cerebral cavernous malformations, and in
preclinical models of this disorder, suggest that the β-blocker propranolol might reduce the …

[HTML][HTML] Cerebral cavernous malformation, familial

L Morrison, A Akers - 2016 - europepmc.org
Cerebral cavernous malformations (CCMs) are vascular malformations in the brain and
spinal cord comprising closely clustered, enlarged capillary channels (caverns) with a single …

The role of propranolol as a repurposed drug in rare vascular diseases

AM Cuesta, E Gallardo-Vara, J Casado-Vela… - International Journal of …, 2022 - mdpi.com
Rare Diseases (RD) are defined by their prevalence in less than 5 in 10,000 of the general
population. Considered individually, each RD may seem insignificant, but together they add …

Circulating biomarkers in familial cerebral cavernous malformation

F Lazzaroni, JMTA Meessen, Y Sun, S Lanfranconi… - …, 2024 - thelancet.com
Summary Background Cerebral Cavernous Malformation (CCM) is a rare cerebrovascular
disease, characterized by the presence of multiple vascular malformations that may result in …

Repurposing of antiangiogenic agents for treatment of vascular anomalies

J Blatt, JE Brondon, EL Nieman, K Phillips… - Pharmacology & …, 2023 - Elsevier
Vascular anomalies (VA) are developmental anomalies of veins, arteries, lymphatics or
capillaries thought to be caused by mutations in genes that drive angiogenesis. Treatments …

Modifiable cardiovascular risk factors in patients with sporadic cerebral cavernous malformations: obesity matters

B Chen, D Saban, S Rauscher, A Herten… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: This study aims to assess the influence of modifiable
cardiovascular risk factors on hemorrhage risk of sporadic cerebral cavernous …